Organ-Tumor-on-a-Chip Market, by Type (Lung Tumor-on-a-chip, Bone Marrow Tumor-on-a-chip, Brain Tumor-on-a-chip, Breast Tumor-on-a-chip, Urinary System Tumor-on-a-chip, Intestine Tumor-on-a-chip, and Liver Tumor-on-a-chip): Global Opportunity Analysis and Industry Forecast, 2021-2030

Organ-Tumor-on-a-Chip Market Statistics

The global organ-tumor-on-a-chip market size was valued at $5,937.27 thousand in 2020, and is projected to reach $117,471.41 thousand by 2030, registering a CAGR of 34.3% from 2021 to 2030. Cancer is one of the leading causes of death, despite enormous efforts to explore cancer biology and develop anticancer therapies. The main challenges in cancer research are establishing an efficient tumor microenvironment in vitro and exploring efficient means for screening anticancer drugs to reveal the nature of cancer and develop treatments. Tumor-on-a-chip is a miniature cell culture device that simulates tumor cell tissue structure and functional units in vitro. Tumor-on-a-chip can be used to simulate tumor growth and expansion, angiogenesis, and progression from early to advanced lesions involving epithelial–mesenchymal transition (EMT), tumor cell invasion and metastasis.

Organ-on-a-chip systems are based on the use of microfluidics to construct tissue models. Tumor-on-a-chip systems have emerged by using cancer-derived cells and related extracellular matrix (ECMs) in tissue-specific structures to replace healthy cells. Therefore, the main processing technology of tumor-on-a-chip systems is the same as that of organ-on-a-chip systems.

There are several key elements in fabricating an integrated organ-on-a-chip, including a microfluidic system, 2D/3D microtissue culturing, stimulus-loading components, and sensors for monitoring and readout of the results. The emerging tumor-on-a-chip platforms integrating 3D cell culture, microfluidic technology, and tissue engineering have successfully mimicked the pivotal structural and functional characteristics of the in vivo tumor microenvironment.

A variety of techniques have been adopted to fabricate tumor-on-a-chip devices, among which the most widely employed are photolithography, replica molding, soft lithography, microcontact printing and bioprinting technology. With the development of materials and manufacturing techniques, such as microfluidics and microprinting, combined with stem cell technology, 3D human tissue-like models known as organoids and spheroids are generated. They can be used in human development research, disease progression, and treatment as well as to develop personalized drug methods. Organoids are 3D cell culture models that can self-organize into complex organ-like tissues. To create biomimetic 3D tumor models that better encapsulate pathologic processes, several important factors in the tumor microenvironment must be considered, including oxygen tension, which is a key regulator of cellular behavior. In contrast to the tumor growth microenvironment in vivo, tumor models in vitro are usually under atmospheric oxygen conditions, which are not representative of the conditions in vivo.

A variety of human-derived in vitro tumor-on-a-chip models have been developed for studying various characteristics associated with tumor progression, such as growth, angiogenesis, metastasis, and drug response. By combining advanced microfabrication techniques, such as photolithography, soft lithography and bioprinting, with microfluidic and tissue engineering techniques, tumor chips can ideally reproduce specific key aspects of the tumor microenvironment, such as biochemical gradients and niche factors, dynamic cell–cell and cell–matrix interactions, and complex tissue structures comprised of tumor and stromal cells. Since the tumor-on-a-chip system is usually composed of cells from a single organ, its recombination ability is limited. To solve this problem, researchers developed multiorgan-on-a-chip systems to evaluate the efficacy and off-target toxicity of anticancer therapeutics.

Impact Of Covid-19 On Organ-tumor-on-a-chip Market (Pre And Post Analysis)

The COVID-19 outbreak has impacted the global organ-tumor-on-a-chip market negatively. The COVID-19 pandemic has resulted in government authorities implementing numerous measures to try to contain the virus, such as travel bans and restrictions, quarantines, shelter-in-place or stay-at-home orders, and business shutdowns, which impacted reliable supply of sufficient human cells or a supply at cost-effective prices, which harmed the business results of operations The extent to which COVID-19 will impact the future developments is highly uncertain and cannot be predicted with confidence, including the rise of vaccine-resistant variants, duration of the outbreak, travel bans, restrictions, quarantines, shelter-in-place or stay-at-home orders, and business shutdowns.

Global Organ-tumor-on-a-chip Market Segmentation

The organ-tumor-on-a-chip market is segmented on the basis of type, and region. By type, the market is segmented into lung tumor-on-a-chip, bone marrow tumor-on-a-chip, brain tumor-on-a-chip, breast tumor-on-a-chip, urinary system tumor-on-a-chip, intestine tumor-on-a-chip, and liver tumor-on-a-chip. 

Region wise, the organ-tumor-on-a-chip market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Segment Review

By type, the lung tumor-on-a-chip segment was the highest revenue generator in 2020, and is anticipated to continue this trend in the future, owing to rising prevalence in lung cancer cases.

By region, North America accounted for the largest organ-tumor-on-a-chip market share in 2020 and is expected to retain its dominance throughout the forecast period, owing to rise in demand for organ-tumor-on-chips in drug screening, especially in the U.S., increase in number of key market players, and research centers in the region.

The major companies profiled in this report include Axosim Technologies LLC, Beonchip S. L., BioIVT LLC, Emulate Inc., InSphero AG, Mimetas B.V., Nortis, Inc., and Organovo Holdings, Inc.

Key Benefits For Stakeholders

• This report provides an extensive analysis of the current and emerging market trends and dynamics in the global organ-tumor-on-a-chip market to identify the prevailing opportunities.
• This study presents the competitive landscape of the global organ-tumor-on-a-chip market to predict the competitive environment across geographies.
• Comprehensive analysis of factors that drive and restrict the organ-tumor-on-a-chip market growth is provided.
• Region- & country-wise analysis is provided to understand the organ-tumor-on-a-chip market trends and dynamics

  Organ-Tumor-on-a-Chip Market, by Type Report Highlights

Aspects	Details
By Type	Lung Tumor-on-a-chip Bone Marrow Tumor-on-a-chip Brain Tumor-on-a-chip Breast Tumor-on-a-chip Urinary System Tumor-on-a-chip Intestine Tumor-on-a-chip Liver Tumor-on-a-chip
By Region	North America  (U.S., Canada, Mexico) Europe  (Germany, France, UK, Italy, Spain, Rest of Europe) Asia-Pacific  (Japan, China, Australia, India, South Korea, Rest of Asia-Pacific) LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
By Key Market Players	Axosim Technologies LLC Beonchip S. L. BioIVT LLC Emulate Inc. InSphero AG Mimetas B.V. Nortis, Inc. Organovo Holdings, Inc.

Analyst Review

This section provides opinions of the top-level CXOs in the organ-tumor-on-a-chip industry. According to CXOs, of leading companies in the market, it has been estimated that the increasing global burden of cancer has significantly mounted over the past decade. As tumor chips can simulate the 3D microstructure and microphysiological functions of in vivo human organs/tissues, providing a better understanding of the mechanisms of tumor growth and metastasis. Thus, the increasing prevalence of cancer is anticipated to support the growth of the organ-tumor-on-a-chip market during the forecast period.

On the contrary, complexity of organ-tumor-on-chip due to esoteric microfabrication technologies makes it difficult to simulate the various complex signal regulation responses of other nonadjacent organs in the human body to cancer, which can hamper the market growth during the forecast period

North America is expected to account for the highest market share in 2020, owing to the rise in demand for organ-tumor-on-chips in drug screening, especially in the U.S., increase in number of key market players, and research centers in the region.

Author Name(s) : Kishor Sherkar| Shubham Choudante | Roshan Deshmukh

Related Tags

• Clinical Trials
• Oncology
• Cancer Drugs
• Oncology Information Systems
• Bioinformatics

^*Terms and Conditions Apply